A primer on recurrent and de novo glomerulonephritis in renal allografts

Nature Clinical Practice Nephrology

Volumn 4, Issue 8, 2008, Pages 446-457

  Ivanyi, Bela ^a  

^a UNIVERSITY OF SZEGED   (Hungary)

Author keywords

De novo; Glomerulonephritis; Kidney allograft; Post transplantation; Recurrence

Indexed keywords

ALPORT SYNDROME; FOCAL GLOMERULOSCLEROSIS; GLOMERULONEPHRITIS; HEMOLYTIC UREMIC SYNDROME; HISTOPATHOLOGY; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY ALLOGRAFT REJECTION; KIDNEY TRANSPLANTATION; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MEMBRANOUS GLOMERULONEPHRITIS; PATHOPHYSIOLOGY; POSTOPERATIVE COMPLICATION; PREVALENCE; PRIORITY JOURNAL; RECURRENCE RISK; REVIEW; RISK FACTOR; THROMBOTIC THROMBOCYTOPENIC PURPURA;

GLOMERULAR BASEMENT MEMBRANE; GLOMERULONEPHRITIS; GLOMERULONEPHRITIS, MEMBRANOUS; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; GRAFT SURVIVAL; HUMANS; KIDNEY GLOMERULUS; KIDNEY TRANSPLANTATION; NEPHROSIS, LIPOID; POSTOPERATIVE COMPLICATIONS; PREVALENCE; PROTEINURIA; RECURRENCE; RISK FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 47949119249     PISSN: 17458323     EISSN: 17458331     Source Type: Journal    
DOI: 10.1038/ncpneph0854     Document Type: Review

References (80)

1. Yakupoglu U et al. (2004) Post-transplant nephrotic syndrome: a comprehensive clinicopathologic study. Kidney Int 65: 2360-2370
2. Chung J et al. (2000) Glomerulonephritis is the major cause of proteinuria in renal transplant recipients: histopathologic findings of renal allografts with proteinuria. Clin Transplant 14: 499-504
3. Suzuki H et al. (2003) Incidence of latent mesangial IgA deposition in renal allograft donors in Japan. Kidney Int 63: 2286-2294
4. Moriyama T et al. (2005) Latent IgA deposition from donor kidney is the major risk factor for recurrent IgA nephropathy in renal transplantation. Clin Transplant 19 (Suppl 14): S41-S48
5. Schwartzman MS et al. (2005) Transplantation and 6-month follow-up of renal transplantation from a donor with systemic lupus erythematosus and lupus nephritis. Am J Transplant 5: 1772-1776
6. Briggs JD and Jones E (1999) Recurrence of glomerulonephritis following renal transplantation. Nephrol Dial Transplant 14: 564-565
7. Chadban S (2001) Glomerulonephritis recurrence in the renal graft. J Am Soc Nephrol 12: 394-402
8. Hariharan S et al. (1998) Recurrent and de novo renal diseases after renal transplantation: a report from the Renal Allograft Disease Registry. Am J Kidney Dis 31: 928-931
9. Hariharan S et al. (1999) Recurrent and de novo glomerular disease after renal transplantation: a report from Renal Allograft Disease Registry (RADR). Transplantation 68: 635-641
10. Briganti EM et al. (2002) Risk of renal allograft loss from recurrent glomerulonephritis. N Engl J Med 347: 103-109
11. Nankivell BJ et al. (2004) Evolution and pathophysiology of renal-transplant glomerulosclerosis. Transplantation 78: 461-468
12. Ibrahim H et al. (2006) Graft loss from recurrent glomerulonephritis is not increased with a rapid steroid discontinuation protocol. Transplantation 81: 214-219
13. Morozumi K et al. (2004) Cyclosporine nephrotoxicity: how does it affect renal allograft function and transplant morphology? Transplant Proc 36 (Suppl 2): 251S-256S
14. Cosio FG et al. (1999) Focal segmental glomerulosclerosis in renal allografts with chronic nephropathy: implications for graft survival. Am J Kidney Dis 34: 731-738
15. Zimmerman S (1984) Increased urinary protein excretion in the rat produced by serum from a patient with recurrent focal glomerular sclerosis after renal transplantation. Clin Nephrol 22: 32-38
16. Sharma M et al. (2002) Proteinuria after injection of human focal segmental glomerulosclerosis factor. Transplantation 73: 366-372
17. Musante L et al. (2002) Characterization of plasma factors that alter the permeability to albumin within isolated glomeruli. Proteomics 2: 197-205
18. Coward RJ et al. (2005) Nephrotic plasma alters slit diaphragm-dependent signaling and translocates nephrin, podocin, and CD2 associated protein in cultured human podocytes. J Am Soc Nephrol 16: 629-637
19. Caridi G et al. (2003) Broadening the spectrum of diseases related to podocin mutations. J Am Soc Nephrol 14: 1278-1286
20. Caridi G et al. (2003) Podocin mutations in sporadic focal-segmental glomerulosclerosis occurring in adulthood. Kidney Int 64: 365
21. Ruf R et al. (2004) Patients with mutations in NPHS2 (podocin) do not respond to standard steroid treatment of nephrotic syndrome. J Am Soc Nephrol 15: 722-732
22. Weber S et al. (2004) NPHS2 mutation analysis shows genetic heterogeneity of steroid-resistant nephrotic syndrome and low post-transplant recurrence. Kidney Int 66: 571-579
23. Carraro M et al. (2002) Serum glomerular permeability activity in patients with podocin mutations (NPHS2) and steroid-resistant nephrotic syndrome. J Am Soc Nephrol 13: 1946-1952
24. Newstead CG (2003) Recurrent disease in renal transplants. Nephrol Dial Transplant 18 (Suppl 6): Svi68-Svi74
25. Swaminathan S et al. (2006) Collapsing and non-collapsing focal segmental glomerulosclerosis in kidney transplants. Nephrol Dial Transplant 21: 2607-2614
26. Adrogue HE et al. (2007) Coincident activation of Th2 T cells with onset of the disease and differential expression of GRO-gamma in peripheral blood leukocytes in minimal change disease. Am J Nephrol 27: 253-261
27. Zafarmand A et al. (2002) De novo minimal change disease associated with reversible post-transplant nephrotic syndrome: a report of five cases and review of literature. Clin Transplant 16: 350-361
28. Ronco P and Debiec H (2005) Molecular pathomechanisms of membranous nephropathy: from Heymann nephritis to alloimmunization. J Am Soc Nephrol 16: 1205-1213
29. Cosyns JP et al. (1998) Recurrence of membranous nephropathy after renal transplantation: probability, outcome and risk factors. Clin Nephrol 50: 144-153
30. Requiao-Moura R et al. (2007) Prognostic factors associated with poor graft outcomes in renal recipients with post-transplant glomerulonephritis. Clin Transplant 21: 363-370
31. Schwarz A et al. (1994) Impact of de novo membranous glomerulonephritis on the clinical course after kidney transplantation. Transplantation 58: 650-654
32. Poduval RD et al. (2003) Treatment of de novo and recurrent membranous nephropathy in renal transplant recipients. Semin Nephrol 23: 392-399
33. Joosten SA et al. (2005) Antibody response against the glomerular basement membrane protein agrin in patients with transplant glomerulopathy. Am J Transplant 5: 383-393
34. Berger SP and Daha MR (2007) Complement in glomerular injury. Semin Immunopathol 29: 375-384
35. Braun MC et al. (2005) Recurrence of membranoproliferative glomerulonephritis type II in renal allografts: the North American Pediatric Renal Transplant Cooperative Study Experience. J Am Soc Nephrol 16: 2225-2233
36. Little MA et al. (2006) Severity of primary MPGN, rather than MPGN type, determines renal survival and post-transplantation recurrence risk. Kidney Int 69: 504-511
37. Levy J et al. (2001) Long-term outcome of antiglomerular basement membrane antibody disease treated with plasma exchange and immunosuppression. Ann Intern Med 134: 1033-1042
38. Khandelwal M et al. (2004) Recurrence of anti-GBM disease 8 years after renal transplantation. Nephrol Dial Transplant 19: 491-494
39. Borza DB et al. (2005) Recurrent Goodpasture's disease secondary to a monoclonal IgA1-kappa antibody autoreactive with the alpha1/alpha2 chains of type IV collagen. Am J Kidney Dis 45: 397-406
40. Nachman PH et al. (1999) Recurrent ANCA-associated small vessel vasculitis after transplantation: a pooled analysis. Kidney Int 56: 1544-1550
41. Elmedhem A et al. (2003) Relapse rate and outcome of ANCA-associated small vessel vasculitis after transplantation. Nephrol Dial Transplant 18: 1001-1004
42. Choy BY et al. (2006) Recurrent glomerulonephritis after kidney transplantation. Am J Transplant 6: 2535-2542
43. Gera M et al. (2007) Recurrence of ANCA-associated vasculitis following renal transplantation in the modern era of immunosupression. Kidney Int 71: 1296-1301
44. Barratt J et al. (2007) Immunopathogenesis of IgAN. Semin Immunopathol 29: 427-443
45. Gough J et al. (2005) Recurrent and de novo glomerular immune-complex deposits in renal transplant biopsies. Arch Pathol Lab Med 129: 231-233
46. Bumgardner GL et al. (1998) Single-center long-term results of renal transplantation for IgA nephropathy. Transplantation 65: 1053-1060
47. Jeong HJ et al. (2004) IgA nephropathy in renal allografts - recurrence and graft dysfunction. Yonsei Med J 45: 1043-1048
48. Chacko B et al. (2007) Outcomes of renal transplantation in patients with immunoglobulin A nephropathy in India. J Postgrad Med 53: 92-95
49. Choy BY et al. (2003) Renal transplantation in patients with primary immunoglobulin A nephropathy. Nephrol Dial Transplant 18: 2399-2404
50. Andresdottir MB et al. (2001) Favorable outcome of renal transplantation in patients with IgA nephropathy. Clin Nephrol 56: 279-288
51. Wang AY et al. (2001) Recurrent IgA nephropathy in renal transplant allografts. Am J Kidney Dis 38: 588-596
52. McDonald S et al. (2006) Recurrence of IgA nephropathy among renal allograft recipients from living donors is greater among those with zero HLA mismatches. Transplantation 82: 759-762
53. Jeong HJ et al. (2004) Glomerular crescents are responsible for chronic graft dysfunction in post-transplant IgA nephropathy. Pathol Int 54: 837-842
54. Coppo R et al. (2007) Serological and genetic factors in early recurrence of IgA nephropathy after renal transplantation. Clin Transplant 21: 728-737
55. Kashtan CE (2006) Renal transplantation in patients with Alport syndrome. Pediatr Transplant 10: 651-657
56. Jais JP et al. (2003) X-linked Alport syndrome: natural history and genotype-phenotype correlations in girls and women belonging to 195 families: a "European Community Alport Syndrome Concerted Action" study. J Am Soc Nephrol 14: 2603-2610
57. Artz MA et al. (2003) Renal transplantation in patients with hemolytic uremic syndrome: high rate of recurrence and increased incidence of acute rejections. Transplantation 76: 821-826
58. Caprioli J et al. (2006) Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment and outcome. Blood 108: 1267-1279
59. Ponticelli C and Banfi G (2006) Thrombotic microangiopathy after kidney transplantation. Transpl Int 19: 789-794
60. Sellier-Leclerc A et al. (2007) Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J Am Soc Nephrol 18: 2392-2400
61. Bresin E et al. (2006) Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: prognostic significance of genetic background. Clin J Am Soc Nephrol 1: 88-99
62. Reynolds JC et al. (2003) Thrombotic microangiopathy after renal transplantation in the United States. Am J Kidney Dis 42: 1058-1068
63. Karthikeyan V et al. (2003) Outcome of plasma exchange therapy in thrombotic microangiopathy after renal transplantation. Am J Transplant 3: 1289-1294
64. Zarifian A et al. (1999) Cyclosporine-associated thrombotic microangiopathy in renal allografts. Kidney Int 55: 2457-2466
65. Schwimmer J et al. (2003) De novo thrombotic microangiopathy in renal transplant recipients: a comparison of hemolytic uremic syndrome with localized renal thrombotic microangiopathy. Am J Kidney Dis 41: 471-479
66. Opelz G et al. (2006) No improvement of patient or graft survival in transplant recipients treated with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers: a collaborative transplant study report. J Am Soc Nephrol 17: 3257-3262
67. Weber S and Tönshoff B (2005) Recurrence of focal-segmental glomerulosclerosis in children after renal transplantation: clinical and genetic aspects. Transplantation 80 (Suppl): S128-S134
68. Vincenti F and Ghiggeri GM (2005) New insights into the pathogenesis and the therapy of recurrent focal glomerulosclerosis. Am J Transplant 5: 1179-1185
69. Yabu JM et al. (2008) Rituximab failed to improve nephrotic syndrome in renal transplant recipients with recurrent focal segmental glomerulosclerosis. Am J Transplant 8: 222-227
70. Fine RN (2007) Recurrence of nephrotic syndrome/focal segmental glomerulosclerosis following renal transplantation in children. Pediatr Nephrol 22: 496-502
71. Ruggenenti P et al. (2006) Rituximab for idiopathic membranous nephropathy: who can benefit? Clin J Am Soc Nephrol 1: 738-748
72. Gallon L and Chhabra D (2006) Anti-CD20 monoclonal antibody (rituximab) for the treatment of recurrent idiopathic membranous nephropathy in a renal transplant patient. Am J Transplant 6: 3017-3021
73. Geetha D et al. (2007) Successful induction of remission with rituximab for relapse of ANCA-associated vasculitis post-kidney transplant: report of two cases. Am J Transplant 7: 2821-2825
74. Courtney AE et al. (2006) Does angiotensin blockade influence graft outcome in renal transplant recipients with IgA nephropathy? Nephrol Dial Transplant 21: 3550-3554
75. Meier-Kriesche HU et al. (2003) Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation. Transplantation 75: 1291-1295
76. Fernández-Fresnedo G et al. (2004) Proteinuria: a new marker of long-term graft and patient survival in kidney transplantation. Nephrol Dial Transplant 19 (Suppl 3): Siii47-Siii51
77. Magee C and Pascual M (2004) Update in renal transplantation. Arch Intern Med 164: 1373-1388
78. Matas AJ (2006) Recurrent disease after kidney transplantation - it is time to unite to address this problem! Am J Transplant 6: 2527-2528
79. Floege J (2003) Recurrent glomerulonephritis following renal transplantation: an update. Nephrol Dial Transplant 18: 1260-1265
80. Noris M and Remuzzi G (2005) Hemolytic uremic syndrome. J Am Soc Nephrol 16: 1035-1050